The PennZone

  • Home
  • Non-profit
  • Technology
  • Business
  • Education
  • Construction
  • Entertainment
  • Health
  • Marketing

HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
The PennZone/10270943

Trending...
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.

The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.

More on The PennZone
  • Tru by Hilton El Paso Airport Opens to Guests
  • Zenylitics Announces Leadership Transition to Continue Accelerated Growth
  • Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
  • Turnstone Creative Expands Leadership Team with Addition of Marketing Manager

The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.

HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • Lord of the Rings, Doctor Who' Q&As, Local Sessions Highlight FAN EXPO Philadelphia Programming
  • Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
  • Tina Hasselbusch, co-founder and CEO of Turnstone Creative, Receives Circle of Excellence from Lehigh Valley Business
  • Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
  • Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
  • AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
  • Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
  • Eichelberger Performing Arts Center Welcomes New Executive Director
  • Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • New Wisconsin Report Shows Most Plane Crashes Happen Outside Major Hubs
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • Book Florida Keys Accommodations Early with KeysCaribbean and Save 15 Percent
  • Color Card Administrator Highlights Growing Enterprise Demand for Workflow Orchestration in Enterprise Business Card Governance
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
  • Curious About Mensa? DFW Event Offers a 1-Day Immersion
  • Morphy's will breeze into summer with a June 10-11 Fine & Decorative Arts auction featuring nearly 1,200 high-quality lots

Popular on PennZone

  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding

Similar on PennZone

  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • TechHouse Earns Highly Selective Microsoft Support Badge
  • J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
  • Zenylitics Announces Leadership Transition to Continue Accelerated Growth
  • Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us